Payment overview · 2025
General Payments
$48.97
3 reported records · 3 companies
Healthcare provider profile · identity verified
Becky Wade, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VENTURA, CA · NPI 1992869986
Verified facts
What the public records show
CMS Open Payments records show Becky Wade, M.D. received $48.97 in general payments during 2025 across 3 reported records.
Abbott Laboratories accounted for 43.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.25 | 43.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.82 | 30.3% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $12.90 | 26.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $48.97 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 628 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 434 | 119 |
| Losartan Potassium | Losartan Potassium | 287 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 260 | 77 |
| Trazodone Hcl | Trazodone Hcl | 252 | 65 |
| Gabapentin | Gabapentin | 226 | 61 |
| Metformin Hcl | Metformin Hcl | 204 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 196 | 56 |
| Lisinopril | Lisinopril | 169 | 41 |
| Alendronate Sodium | Alendronate Sodium | 134 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 34 |
| Sertraline Hcl | Sertraline Hcl | 120 | 35 |
| Estradiol | Estradiol | 116 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 34 |
| Omeprazole | Omeprazole | 104 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 14 |
| Trulicity | Dulaglutide | 87 | 14 |
| Carvedilol | Carvedilol | 86 | 24 |
| Furosemide | Furosemide | 86 | 22 |
| Simvastatin | Simvastatin | 84 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 46 |
| Jardiance | Empagliflozin | 81 | 22 |
| Eliquis | Apixaban | 80 | 15 |
| Bupropion Xl | Bupropion Hcl | 75 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 24 |
| Montelukast Sodium | Montelukast Sodium | 64 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 15 |
| Spironolactone | Spironolactone | 61 | 17 |
| Valsartan | Valsartan | 57 | 11 |
| Ezetimibe | Ezetimibe | 53 | 15 |
| Ozempic | Semaglutide | 53 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 16 |
| Prednisone | Prednisone | 53 | 45 |
| Synthroid | Levothyroxine Sodium | 53 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 16 |
| Valacyclovir | Valacyclovir Hcl | 47 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 41 | suppressed |
| Cephalexin | Cephalexin | 40 | 35 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 15 |
| Lovastatin | Lovastatin | 38 | 12 |
| Potassium Chloride | Potassium Chloride | 35 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Famotidine | Famotidine | 30 | 12 |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Lactulose | Lactulose | 23 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | 11 |
| Carbamazepine Er | Carbamazepine | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Prolia | Denosumab | 17 | 12 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Savaysa | Edoxaban Tosylate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $48.97 · 3 records | Abbott Laboratories | AIRSUPRA, FREESTYLE LIBRE 3 | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error